Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 591 entries
Sorted by: Best Match Show Resources per page
Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.

Journal of pediatric hematology/oncology

Wedekind MF, Saraf A, Willen F, Audino AN.
PMID: 33769385
J Pediatr Hematol Oncol. 2021 Mar 23; doi: 10.1097/MPH.0000000000002147. Epub 2021 Mar 23.

Peripheral T-cell lymphoma (PTCL) is an aggressive tumor, rarely seen in pediatrics or adolescent and young adults (AYAs) so there is no upfront or relapsed standard of care. The authors describe a 16-year-old with PTCL, treated with chemotherapy and...

Cite
Wedekind MF, Saraf A, Willen F, et al. Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2021;doi: 10.1097/MPH.0000000000002147.
Wedekind, M. F., Saraf, A., Willen, F., & Audino, A. N. (2021). Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature. Journal of pediatric hematology/oncology, . https://doi.org/10.1097/MPH.0000000000002147
Wedekind, Mary Frances, et al. "Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature." Journal of pediatric hematology/oncology vol. (2021). doi: https://doi.org/10.1097/MPH.0000000000002147
Wedekind MF, Saraf A, Willen F, Audino AN. Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2021 Mar 23; doi: 10.1097/MPH.0000000000002147. Epub 2021 Mar 23. PMID: 33769385.
Copy Download .nbib Format: NLM
The Unique Balancing Act of Managing Children With Cancer and COVID-19 Infection: A Single Center Experience From South India.

Journal of pediatric hematology/oncology

Totadri S, Srinivasan HN, Joseph LL, Boddu D, Suresh Kochath P, Moorthy M, Mathew LG, John RR.
PMID: 33769391
J Pediatr Hematol Oncol. 2021 Mar 23; doi: 10.1097/MPH.0000000000002148. Epub 2021 Mar 23.

Children with cancer are vulnerable to severe infections. Balancing the intensive treatment of cancer, with the potential risk of coronavirus disease-2019 (COVID-19) related morbidity and mortality is a unique challenge. Children with cancer testing positive for severe acute respiratory...

Cite
Totadri S, Srinivasan HN, Joseph LL, et al. The Unique Balancing Act of Managing Children With Cancer and COVID-19 Infection: A Single Center Experience From South India. J Pediatr Hematol Oncol. 2021;doi: 10.1097/MPH.0000000000002148.
Totadri, S., Srinivasan, H. N., Joseph, L. L., Boddu, D., Suresh Kochath, P., Moorthy, M., Mathew, L. G., & John, R. R. (2021). The Unique Balancing Act of Managing Children With Cancer and COVID-19 Infection: A Single Center Experience From South India. Journal of pediatric hematology/oncology, . https://doi.org/10.1097/MPH.0000000000002148
Totadri, Sidharth, et al. "The Unique Balancing Act of Managing Children With Cancer and COVID-19 Infection: A Single Center Experience From South India." Journal of pediatric hematology/oncology vol. (2021). doi: https://doi.org/10.1097/MPH.0000000000002148
Totadri S, Srinivasan HN, Joseph LL, Boddu D, Suresh Kochath P, Moorthy M, Mathew LG, John RR. The Unique Balancing Act of Managing Children With Cancer and COVID-19 Infection: A Single Center Experience From South India. J Pediatr Hematol Oncol. 2021 Mar 23; doi: 10.1097/MPH.0000000000002148. Epub 2021 Mar 23. PMID: 33769391.
Copy Download .nbib Format: NLM
The announcement of treatment resistance from the pediatric oncologist's point of view: a qualitative study.

Pediatric hematology and oncology

Terrasson J, Seigneur É, Rault A, El Mellah L, Dolbeault S, Brédart A.
PMID: 34392770
Pediatr Hematol Oncol. 2021 Aug 16;1-13. doi: 10.1080/08880018.2021.1956030. Epub 2021 Aug 16.

Breaking bad news in pediatric oncology covers widely diverse clinical situations. The aim of this study was to highlight the specificities of the announcement of treatment resistance as perceived by pediatric oncologists, particularly in comparison with the disclosure of...

Cite
Terrasson J, Seigneur É, Rault A, et al. The announcement of treatment resistance from the pediatric oncologist's point of view: a qualitative study. Pediatr Hematol Oncol. 2021;1-13doi: 10.1080/08880018.2021.1956030.
Terrasson, J., Seigneur, �. �., Rault, A., El Mellah, L., Dolbeault, S., & Brédart, A. (2021). The announcement of treatment resistance from the pediatric oncologist's point of view: a qualitative study. Pediatric hematology and oncology, 1-13. https://doi.org/10.1080/08880018.2021.1956030
Terrasson, Johanna, et al. "The announcement of treatment resistance from the pediatric oncologist's point of view: a qualitative study." Pediatric hematology and oncology vol. (2021): 1-13. doi: https://doi.org/10.1080/08880018.2021.1956030
Terrasson J, Seigneur É, Rault A, El Mellah L, Dolbeault S, Brédart A. The announcement of treatment resistance from the pediatric oncologist's point of view: a qualitative study. Pediatr Hematol Oncol. 2021 Aug 16;1-13. doi: 10.1080/08880018.2021.1956030. Epub 2021 Aug 16. PMID: 34392770.
Copy Download .nbib Format: NLM
Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort.

Journal of pediatric hematology/oncology

Takahashi T, Turcotte LM, Gordon PM, Johnson AD, Rubin N, Spector LG.
PMID: 33735152
J Pediatr Hematol Oncol. 2021 May 05; doi: 10.1097/MPH.0000000000002140. Epub 2021 May 05.

Leukapheresis (LA) in pediatric leukemia is performed for leukostasis, a life-threatening emergency in the setting of extremely increased blast cell counts. The authors aimed to assess the epidemiology of pediatric leukemia who received LA. The authors reviewed US nationally...

Cite
Takahashi T, Turcotte LM, Gordon PM, et al. Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort. J Pediatr Hematol Oncol. 2021;doi: 10.1097/MPH.0000000000002140.
Takahashi, T., Turcotte, L. M., Gordon, P. M., Johnson, A. D., Rubin, N., & Spector, L. G. (2021). Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort. Journal of pediatric hematology/oncology, . https://doi.org/10.1097/MPH.0000000000002140
Takahashi, Takuto, et al. "Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort." Journal of pediatric hematology/oncology vol. (2021). doi: https://doi.org/10.1097/MPH.0000000000002140
Takahashi T, Turcotte LM, Gordon PM, Johnson AD, Rubin N, Spector LG. Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort. J Pediatr Hematol Oncol. 2021 May 05; doi: 10.1097/MPH.0000000000002140. Epub 2021 May 05. PMID: 33735152; PMCID: PMC8568727.
Copy Download .nbib Format: NLM
Hemolymphangioma invasion of R scapula and mediastinum: a rare case report.

Pediatric hematology and oncology

Ying Q, Cui S, Zhou K, Chen Y, Wei P, Ye Q.
PMID: 34355653
Pediatr Hematol Oncol. 2021 Aug 06;1-6. doi: 10.1080/08880018.2021.1956659. Epub 2021 Aug 06.

No abstract available.

Cite
Ying Q, Cui S, Zhou K, et al. Hemolymphangioma invasion of R scapula and mediastinum: a rare case report. Pediatr Hematol Oncol. 2021;1-6doi: 10.1080/08880018.2021.1956659.
Ying, Q., Cui, S., Zhou, K., Chen, Y., Wei, P., & Ye, Q. (2021). Hemolymphangioma invasion of R scapula and mediastinum: a rare case report. Pediatric hematology and oncology, 1-6. https://doi.org/10.1080/08880018.2021.1956659
Ying, Qianqian, et al. "Hemolymphangioma invasion of R scapula and mediastinum: a rare case report." Pediatric hematology and oncology vol. (2021): 1-6. doi: https://doi.org/10.1080/08880018.2021.1956659
Ying Q, Cui S, Zhou K, Chen Y, Wei P, Ye Q. Hemolymphangioma invasion of R scapula and mediastinum: a rare case report. Pediatr Hematol Oncol. 2021 Aug 06;1-6. doi: 10.1080/08880018.2021.1956659. Epub 2021 Aug 06. PMID: 34355653.
Copy Download .nbib Format: NLM
Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy.

Journal of pediatric hematology/oncology

Youssef MAM, Salah Eldin EM, Osman NS.
PMID: 33974586
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e96-e100. doi: 10.1097/MPH.0000000000002160.

SUMMARY: Dexamethasone is approved as second-line therapy in pediatric chronic immune thrombocytopenic purpura (ITP). Several B-cell abnormalities have been described in ITP pathogenesis.This study assessed the effects of high-dose dexamethasone (HD-DXM) on the percentages and absolute counts of CD19+CD24hiCD38hi...

Cite
Youssef MAM, Salah Eldin EM, Osman NS. Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy. J Pediatr Hematol Oncol. 2022;44(1):e96-e100doi: 10.1097/MPH.0000000000002160.
Youssef, M. A. M., Salah Eldin, E. M., & Osman, N. S. (2022). Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy. Journal of pediatric hematology/oncology, 44(1), e96-e100. https://doi.org/10.1097/MPH.0000000000002160
Youssef, Mervat A M, et al. "Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy." Journal of pediatric hematology/oncology vol. 44,1 (2022): e96-e100. doi: https://doi.org/10.1097/MPH.0000000000002160
Youssef MAM, Salah Eldin EM, Osman NS. Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e96-e100. doi: 10.1097/MPH.0000000000002160. PMID: 33974586.
Copy Download .nbib Format: NLM
Multisystem Inflammatory Syndrome in a Pediatric Patient With Sickle Cell Disease and COVID-19: A Case Report.

Journal of pediatric hematology/oncology

Español MG, Gardner RV, Alicea-Marrero MM, Marrero-Rivera G, Bradford T, LeBlanc DM, Velez MC.
PMID: 34001792
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e134-e137. doi: 10.1097/MPH.0000000000002191.

To this day, there are limited data about the effects and management of coronavirus disease infection in pediatric patients with sickle cell disease. We present the management and successful clinical course of an 8-year-old female with homozygous sickle cell...

Cite
Español MG, Gardner RV, Alicea-Marrero MM, et al. Multisystem Inflammatory Syndrome in a Pediatric Patient With Sickle Cell Disease and COVID-19: A Case Report. J Pediatr Hematol Oncol. 2022;44(1):e134-e137doi: 10.1097/MPH.0000000000002191.
Español, M. G., Gardner, R. V., Alicea-Marrero, M. M., Marrero-Rivera, G., Bradford, T., LeBlanc, D. M., & Velez, M. C. (2022). Multisystem Inflammatory Syndrome in a Pediatric Patient With Sickle Cell Disease and COVID-19: A Case Report. Journal of pediatric hematology/oncology, 44(1), e134-e137. https://doi.org/10.1097/MPH.0000000000002191
Español, María G, et al. "Multisystem Inflammatory Syndrome in a Pediatric Patient With Sickle Cell Disease and COVID-19: A Case Report." Journal of pediatric hematology/oncology vol. 44,1 (2022): e134-e137. doi: https://doi.org/10.1097/MPH.0000000000002191
Español MG, Gardner RV, Alicea-Marrero MM, Marrero-Rivera G, Bradford T, LeBlanc DM, Velez MC. Multisystem Inflammatory Syndrome in a Pediatric Patient With Sickle Cell Disease and COVID-19: A Case Report. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e134-e137. doi: 10.1097/MPH.0000000000002191. PMID: 34001792.
Copy Download .nbib Format: NLM
Bacteremia in Febrile, Non-neutropenic, and Well-appearing Children With Cancer.

Journal of pediatric hematology/oncology

Beauchemin M, Marshall AF, Ricci AM, Lopez ID, Yao Y, Lee A, Jin Z, Sulis ML.
PMID: 34001793
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e194-e198. doi: 10.1097/MPH.0000000000002201.

Fever in a neutropenic pediatric oncology patient requires prompt assessment due to the risk of infectious complications. The appropriate management of fever in non-neutropenic patients, however, is not well-established. We describe the rate of bacteremia in a cohort of...

Cite
Beauchemin M, Marshall AF, Ricci AM, et al. Bacteremia in Febrile, Non-neutropenic, and Well-appearing Children With Cancer. J Pediatr Hematol Oncol. 2022;44(1):e194-e198doi: 10.1097/MPH.0000000000002201.
Beauchemin, M., Marshall, A. F., Ricci, A. M., Lopez, I. D., Yao, Y., Lee, A., Jin, Z., & Sulis, M. L. (2022). Bacteremia in Febrile, Non-neutropenic, and Well-appearing Children With Cancer. Journal of pediatric hematology/oncology, 44(1), e194-e198. https://doi.org/10.1097/MPH.0000000000002201
Beauchemin, Melissa, et al. "Bacteremia in Febrile, Non-neutropenic, and Well-appearing Children With Cancer." Journal of pediatric hematology/oncology vol. 44,1 (2022): e194-e198. doi: https://doi.org/10.1097/MPH.0000000000002201
Beauchemin M, Marshall AF, Ricci AM, Lopez ID, Yao Y, Lee A, Jin Z, Sulis ML. Bacteremia in Febrile, Non-neutropenic, and Well-appearing Children With Cancer. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e194-e198. doi: 10.1097/MPH.0000000000002201. PMID: 34001793; PMCID: PMC8599517.
Copy Download .nbib Format: NLM
Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein.

Journal of pediatric hematology/oncology

Cuntz F, Deubzer HE, Schulte JH, Nimtz-Talaska A, Eggert A, Holzhauer S.
PMID: 33661164
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e246-e249. doi: 10.1097/MPH.0000000000002109.

In the rare co-occurrence of childhood cancer and severe hemophilia, hemostatic management is of paramount therapeutic importance. We present the case of an 11-month-old boy with severe congenital hemophilia B, who was diagnosed with metastatic high-risk neuroblastoma. He consequently...

Cite
Cuntz F, Deubzer HE, Schulte JH, et al. Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein. J Pediatr Hematol Oncol. 2022;44(1):e246-e249doi: 10.1097/MPH.0000000000002109.
Cuntz, F., Deubzer, H. E., Schulte, J. H., Nimtz-Talaska, A., Eggert, A., & Holzhauer, S. (2022). Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein. Journal of pediatric hematology/oncology, 44(1), e246-e249. https://doi.org/10.1097/MPH.0000000000002109
Cuntz, Franziska, et al. "Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein." Journal of pediatric hematology/oncology vol. 44,1 (2022): e246-e249. doi: https://doi.org/10.1097/MPH.0000000000002109
Cuntz F, Deubzer HE, Schulte JH, Nimtz-Talaska A, Eggert A, Holzhauer S. Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e246-e249. doi: 10.1097/MPH.0000000000002109. PMID: 33661164.
Copy Download .nbib Format: NLM
Mesial Temporal Sclerosis as Late Consequence of Posterior Reversible Encephalopathy Syndrome in Pediatric Hemato-oncologic Patients.

Journal of pediatric hematology/oncology

Faraci M, Nobile G, Nobili L, Masetti R, Cordelli D, Toni F, Giardino S, Morana G, Mancardi MM.
PMID: 33661175
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e168-e175. doi: 10.1097/MPH.0000000000002139.

OBJECTIVES: Drug resistant epilepsy has rarely been reported following posterior reversible encephalopathy syndrome (PRES), with few cases of mesial temporal sclerosis (MTS). The aim of this study was to report clinical and neuroimaging features of MTS subsequent to PRES...

Cite
Faraci M, Nobile G, Nobili L, et al. Mesial Temporal Sclerosis as Late Consequence of Posterior Reversible Encephalopathy Syndrome in Pediatric Hemato-oncologic Patients. J Pediatr Hematol Oncol. 2022;44(1):e168-e175doi: 10.1097/MPH.0000000000002139.
Faraci, M., Nobile, G., Nobili, L., Masetti, R., Cordelli, D., Toni, F., Giardino, S., Morana, G., & Mancardi, M. M. (2022). Mesial Temporal Sclerosis as Late Consequence of Posterior Reversible Encephalopathy Syndrome in Pediatric Hemato-oncologic Patients. Journal of pediatric hematology/oncology, 44(1), e168-e175. https://doi.org/10.1097/MPH.0000000000002139
Faraci, Maura, et al. "Mesial Temporal Sclerosis as Late Consequence of Posterior Reversible Encephalopathy Syndrome in Pediatric Hemato-oncologic Patients." Journal of pediatric hematology/oncology vol. 44,1 (2022): e168-e175. doi: https://doi.org/10.1097/MPH.0000000000002139
Faraci M, Nobile G, Nobili L, Masetti R, Cordelli D, Toni F, Giardino S, Morana G, Mancardi MM. Mesial Temporal Sclerosis as Late Consequence of Posterior Reversible Encephalopathy Syndrome in Pediatric Hemato-oncologic Patients. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e168-e175. doi: 10.1097/MPH.0000000000002139. PMID: 33661175.
Copy Download .nbib Format: NLM
Therapy-related Myeloid Neoplasms in Children: A Single-institute Study.

Journal of pediatric hematology/oncology

Li G, Holly T, Kelly DR, Reddy V, Mikhail FM, Carroll AJ, Kutny MA.
PMID: 33625084
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e109-e113. doi: 10.1097/MPH.0000000000002097.

Therapy-related myeloid neoplasm (t-MN) in the pediatric population is not well characterized. We studied 12 pediatric patients diagnosed with t-MN in our institution since 2006. The median age at the t-MN diagnoses was 14.8 years (range, 9 to 20...

Cite
Li G, Holly T, Kelly DR, et al. Therapy-related Myeloid Neoplasms in Children: A Single-institute Study. J Pediatr Hematol Oncol. 2022;44(1):e109-e113doi: 10.1097/MPH.0000000000002097.
Li, G., Holly, T., Kelly, D. R., Reddy, V., Mikhail, F. M., Carroll, A. J., & Kutny, M. A. (2022). Therapy-related Myeloid Neoplasms in Children: A Single-institute Study. Journal of pediatric hematology/oncology, 44(1), e109-e113. https://doi.org/10.1097/MPH.0000000000002097
Li, Geling, et al. "Therapy-related Myeloid Neoplasms in Children: A Single-institute Study." Journal of pediatric hematology/oncology vol. 44,1 (2022): e109-e113. doi: https://doi.org/10.1097/MPH.0000000000002097
Li G, Holly T, Kelly DR, Reddy V, Mikhail FM, Carroll AJ, Kutny MA. Therapy-related Myeloid Neoplasms in Children: A Single-institute Study. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e109-e113. doi: 10.1097/MPH.0000000000002097. PMID: 33625084.
Copy Download .nbib Format: NLM
Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation.

Journal of pediatric hematology/oncology

Donigian S, Whiteway SL, Hipp SJ, Lybeck D, Clark RO.
PMID: 33633024
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e268-e271. doi: 10.1097/MPH.0000000000002112.

Malignant giant cell tumor of bone (GCTB) is a rare, aggressive, sarcoma occurring in adolescent and young adults. It is characterized by the presence of multinucleated giant cells and an aggressive clinical course. Because of the rarity of this...

Cite
Donigian S, Whiteway SL, Hipp SJ, et al. Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation. J Pediatr Hematol Oncol. 2022;44(1):e268-e271doi: 10.1097/MPH.0000000000002112.
Donigian, S., Whiteway, S. L., Hipp, S. J., Lybeck, D., & Clark, R. O. (2022). Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation. Journal of pediatric hematology/oncology, 44(1), e268-e271. https://doi.org/10.1097/MPH.0000000000002112
Donigian, Sara, et al. "Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation." Journal of pediatric hematology/oncology vol. 44,1 (2022): e268-e271. doi: https://doi.org/10.1097/MPH.0000000000002112
Donigian S, Whiteway SL, Hipp SJ, Lybeck D, Clark RO. Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e268-e271. doi: 10.1097/MPH.0000000000002112. PMID: 33633024.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 591 entries